Cardiac Ablation Technologies Market Size Will Attain USD 12.6 Billion by 2030 growing at 11.6% CAGR – Exclusive Report by Acumen Research and Consulting – Yahoo Finance
Acumen Research and Consulting recently published report titled “Cardiac Ablation Technologies Market Report and Region Forecast, 2022 – 2030”
LOS ANGELES , Nov. 28, 2022 (GLOBE NEWSWIRE) — The Global Cardiac Ablation Technologies Market Size accounted for USD 4.8 Billion in 2021 and is projected to occupy a market size of USD 12.6 Billion by 2030 growing at a CAGR of 11.6% from 2022 to 2030.
Cardiac Ablation Technologies Market Statistics
Global cardiac ablation technologies market value was USD 4.8 Billion in 2021 and expected to grow at CAGR of 11.6% from 2022 to 2030
North America cardiac ablation technologies market revenue accounts around 41% share in 2021
According to the CDC, 697,000 people died from heart disease in the United States in 2020
Asia-Pacific cardiac ablation technologies market growth will register considerable CAGR of over 12% from 2022 to 2030
Among technology type, radiofrequency gathered USD 2.6 billion revenue in 2021
Based on end-use, energy-based technology occupied approximately USD 3 billion revenue in 2021
Rising technological advancements in these technologies is a global cardiac ablation technologies market trend driving the industry demand
Cardiac Ablation Technologies Market Growth Factors
Growing incidences of cardiac arrhythmias
Rising geriatric people across the world
Growing trend for minimally invasive procedures
Request For Free Sample Report @ https://www.acumenresearchandconsulting.com/request-sample/1190
Cardiac Ablation Technologies Market Report Coverage:
Market
Cardiac Ablation Technologies Market
Cardiac Ablation Technologies Market Size 2021
USD 4.8 Billion
Cardiac Ablation Technologies Market Forecast 2030
USD 12.6 Billion
Cardiac Ablation Technologies Market CAGR During 2022 – 2030
11.6%
Cardiac Ablation Technologies Market Analysis Period
2018 – 2030
Cardiac Ablation Technologies Market Base Year
2021
Cardiac Ablation Technologies Market Forecast Data
2022 – 2030
Segments Covered
By Technology Type, By Application, By End-User, And By Geography
Cardiac Ablation Technologies Market Regional Scope
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled
Medtronic Plc, St. Jude Medical, Inc. (Abbott), Stryker Corporation, MicroPort Scientific Corporation, Boston Scientific Corporation, CardioFocus Inc., and Biosense Webster, Inc. (Johnson & Johnson),and CONMED Corporation etc.
Report Coverage
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Cardiac Ablation Technologies Market Dynamics
The growing elderly population in developed countries is expected to propel the global cardiac ablation technologies market forward.
There are several factors driving the growth of the global cardiac ablation technologies market, including an increase in cardiovascular disease patients, an ageing population, technological breakthroughs in the field of ablation devices, and rising awareness about the numerous advantages of cardiac ablation procedures over conventional procedures. However, stringent measures implemented by several governments, as well as ongoing healthcare reforms in the United States, are major factors that may have a negative impact on the expansion of the cardiac ablation technologies market. Untapped growth opportunities exist in emerging countries such as China, Mexico, and India for players involved in the manufacturing and consumption of cardiac ablation products. A variety of factors, including increasing ablation adoption in disease treatment and rising market penetration of product manufacturers across numerous developing countries, are providing opportunities for growth for key participants in the cardiac ablation technologies market.
Increased awareness of minimally invasive procedures leads to increased adoption because there is less pain and scarring, and it is also less expensive than traditional surgeries. Tissue removal involves a variety of ablation techniques. In the treatment of numerous prostate, lung, and liver tumours, minimally invasive surgeries are emerging as a possible substitute for conventional therapeutic surgeries. Furthermore, the use of advanced robotic technologies in the cardiac ablation process is safer and more accurate. As a result, the advancement of technology in ablation devices is anticipated to create growth opportunities for the cardiac ablation technologies market in the coming years.
Check the detailed table of contents of the report @
https://www.acumenresearchandconsulting.com/table-of-content/cardiac-ablation-technologies-market
Cardiac Ablation Technologies Market Segmentation
The global market for cardiac ablation technologies is divided into four segments: technology type, application, end-user, and region. The global cardiac ablation technologies market is divided into cryoablation, radiofrequency, laser, microwave, ultrasound, and others based on technology type. The global cardiac ablation technologies market is divided into three applications: atrial fibrillation, ventricular tachycardia, and ophthalmic applications. End-user segment comprises hospitals, ambulatory surgical centers, and cardiac centers. Furthermore, the global cardiac ablation technologies market is divided into five regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
Cardiac Ablation Technologies Market Share
The radiofrequency segment accounted for approximately 56% of the global market in terms of technology type. Atrial fibrillation is expected to have a significant market share between 2022 and 2030, according to the cardiac ablation technologies market forecast. As per the global cardiac ablation technologies industry analysis, hospitals accounted for a sizable portion of total end-user shares in 2021 and are expected to grow significantly over the forecast period.
Cardiac Ablation Technologies Market Regional Growth
North America and Europe held the lion’s share of the global cardiac ablation technologies market, followed by Asia-Pacific and Latin America. The presence of a large geriatric population, as well as the high prevalence of several heart rhythm conditions such as atrial fibrillation (AF), tachycardia, and atrial flutter, fueled demand for cardiac ablation technologies in these regions. The Asia-Pacific cardiac ablation technologies market is expected to grow at a faster CAGR during the forecast period. The region’s market is expected to be fueled in the coming years by an increase in health awareness and health care expenditure. Furthermore, low-cost manufacturing in developing countries is spurring growth in the Asia-Pacific region.
Buy this premium research report –
https://www.acumenresearchandconsulting.com/buy-now/0/1190
Cardiac Ablation Technologies Market Players
The key players catering to the global cardiac ablation technologies market are Advanced Cardiac Therapeutics, Alcon Laboratories Inc., Biosense Webster, Inc. (Johnson & Johnson), Boston Scientific Corporation, CardioFocus Inc., CONMED Corporation, Medtronic Plc, MicroPort Scientific Corporation, Olympus Corporation, St. Jude Medical, Inc. (Abbott), and Stryker Corporation. These companies have established their prominent position in the global market and has huge customer base. These companies have established a strong presence in the global market and have a large customer base. They have a diverse product offering and a global distribution system for cardiac ablation products. Furthermore, the entry of small businesses, particularly in Asia Pacific’s developing markets, is being observed. Strict government regulations and high-quality standards set by market leaders, on the other hand, are expected to limit the growth of new players in the global cardiac ablation technologies market. Partnerships, new product launches, acquisitions, and mergers are all important strategic initiatives undertaken by global corporations. Increasing R&D investments, along with technological advancements to commercialize highly efficient ablation products, are expected to provide lucrative opportunities for industry players in the global cardiac ablation technologies market.
Questions Answered By This Report
What was the market size of Cardiac Ablation Technologies Market in 2021?
What will be the CAGR of Cardiac Ablation Technologies Market during the forecast period from 2022 to 2030?
Who are the major players in Global Cardiac Ablation Technologies Market?
Which region held the largest share in Cardiac Ablation Technologies Market in 2021?
What are the key market drivers of Cardiac Ablation Technologies Market?
Who is the largest end user Cardiac Ablation Technologies Market?
What will be the Cardiac Ablation Technologies Market value in 2030?
Browse More Research Topic on Healthcare Sector Related:
Cardiac Arrhythmia Monitoring Devices Market size accounted for USD 6,485 Million in 2021 and is expected to reach USD 11,490 Million by 2030 with a considerable CAGR of 6.8% during the forecast timeframe of 2022 to 2030.
Cardiac Rhythm Management Devices Market is expected to grow at a CAGR of around 7.5% from 2020 to 2027 and expected to reach the market value of around USD 25.5 Billion by 2027.
The Global Cardiology Market is expected to grow at a CAGR of around 8.8% from 2020 to 2027 and projected to reach the market value of around USD 24.3 Billion by 2027.
About Acumen Research and Consulting:
Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
For Latest Update Follow Us on Twitter , Instagram and LinkedIn
Contact Us:
Mr. Richard Johnson
Acumen Research and Consulting
USA: +13474743864
India: +918983225533
E-mail: sales@acumenresearchandconsulting.com
With less than two years remaining until US voters will decide who will serve as president of the United States from January 2025 to January 2029, former Republican government officials are starting to jockey for position in the coming fight for the 2024 GOP presidential nomination, while at least one prominent Democrat (California governor Gavin Newsom) has reportedly pledged not to challenge President Joe Biden in a Democratic primary. Mr Biden is the current president of the United States and has said on multiple occasions that he intends to run for reelection in 2024. The only US president in recent memory to forgo a run for a second term was the 37th occupant of that office, President Lyndon Johnson.
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Investors may be reacting to positive short-term news, but a longer-term development also provided them with a boost of confidence.
Investors looking for a guiding hand to steer them safely through the current hazardous stock market landscape could do worse than listen to what billionaire Ken Fisher has to say. The Fisher Investments founder famously started his independent money management firm with $250 in 1979, a company that is now a $197-plus billion going concern, while Fisher’s own net worth stands north of $5 billion. So, for those getting restless from 2022’s unrelenting bear, Fisher has some very simple advice: "Th
Cathie Wood and Warren Buffett have extremely different approaches when it comes to investing. While Wood tends to invest in high-flying growth stocks, Buffett is usually seen as a value investor who also loves companies that return capital to shareholders. Buffett has said in the past that he wouldn't buy all of the Bitcoin in the world for $25.
Shares of Israeli container shipping company ZIM Integrated Shipping Services (NYSE: ZIM) tumbled 3.4% through 11:05 a.m. EST Monday — and it's no huge secret why. Across the shipping world, stocks including ZIM, Costamere, and Danaos Corporation are all sliding today. As multiple media outlets have reported, protests against a government "zero-Covid" policy are spreading across China, threatening both the ruling regime's stability, the country's economy, and its ability to produce products that would need container shipping services to reach foreign markets.
With a yield of 9.62%, the recently expired Series I bond was understandably popular. With interest rates rising, bond funds are down this year and banks continue to offer miserly rates on deposit accounts. So it's no wonder that a … Continue reading → The post It Pays to Procrastinate: The New 6.89% I bonds Will Beat the Old 9.62% Bonds in Just 4 Years appeared first on SmartAsset Blog.
Shares of XPeng (NYSE: XPEV), a Chinese electric-vehicle (EV) maker, were soaring today, as some investors grew optimistic that COVID-related protests in China could encourage the government to ease away from its strict policies. Investors are hoping that the protests could lead to an easing of the policies and make it easier for XPeng and other Chinese companies to conduct business. The disruptions in the country had led many investors to ditch Chinese stocks over the past year and have been part of the reason why XPeng's share price is down 85% year to date.
Canoo (NASDAQ: GOEV) has been one of the market's worst-performing electric vehicle stocks. Lastly, Canoo continued to burn cash as its liquidity dried up. Walmart also gained a warrant that gave it the option to buy more than a fifth of Canoo's outstanding shares at $2.15 per share.
REIT stocks have fallen more than the S&P 500, but a potential decline in interest rates next year may revive the sector.
If 2022 ended right now, it would be the worst year for the stock market since the financial system collapsed in the subprime mortgage crisis of 2008. As of this writing, the tech-heavy Nasdaq-100 index is down 28% year to date, though that's a modest decline compared to many formerly high-flying companies that have shed 50% (or more) of their value in 2022. 2022 hasn't been a good year to be in the lending business, particularly for financial technology company Upstart Holdings (NASDAQ: UPST).
All these Berkshire Hathaway holdings are down more than 35% this year. Overall, Buffett's Berkshire Hathaway is having a good year. If you're having a tough time in the market this year, know that Buffett is too.
In this article, we will discuss the 12 best falling stocks to buy now. If you want to explore similar stocks, you can read 5 Best Falling Stocks to Buy Now. We are approaching the end of the year which has been terrible for the markets. Fears of recession, the Ukraine war, supply chain woes, […]
The post-COVID slowdown hasn't been kind to Amazon (NASDAQ: AMZN), and the stock is down 45% so far this year. While the company's e-commerce operations are experiencing weak growth and margins, Amazon is much more than just an online retailer. Amazon's third-quarter results were a mixed bag.
What happened Shares of Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biotech that specializes in therapies to treat neurodegenerative and neurodevelopmental diseases, fell by 23.5% on Monday.
Rallies within the bear market are a good time to reallocate portfolios— and staying in cash isn’t a bad idea, says one strategist.
Lordstown Motors, the embattled EV truck maker, finally has some good news to share with the automotive world — and investors. The company’s long-awaited EV pickup, the Endurance, has achieved full homologation, meaning it now complies with safety requirements for sale in the U.S., the company said. In addition, the Endurance has received EPA and CARB (California Air Resources Board) certification, meaning it is now rated by both agencies.
Income investors dream of buying stocks whose companies have solid business models and fundamentals, but because of temporary market conditions, the shares have ultra-high yields. When markets sell off as a whole those dreams may come true, but other times dreams turn into nightmares if poor earnings cause dividends to be cut and share prices to tumble even further. Take a look at three real estate investment trusts (REITs) with massive dividend yields and decipher whether they are likely to rew
In this article, we discuss the 11 safe energy stocks for a retirement stock portfolio. If you want to read about some more energy stocks, go directly to Retirement Stock Portfolio: 5 Safe Energy Stocks to Consider. The energy sector has been one of the best performers in the S&P 500 over the past few […]
On Dec. 22 , C3.ai's (NYSE: AI) stock closed at an all-time high of $177.47, boosting its market cap to $17 billion. At the time, many investors were dazzled by C3's stellar revenue growth and the disruptive potential of its enterprise artificial intelligence (AI) algorithms — which can be integrated into an organization's existing software infrastructure to cut costs, optimize workflows, improve employee safety standards, and detect fraud.